摘要
目的:分析高果糖饮食诱导的小鼠血清代谢物变化,探讨青蒿素改善高果糖饮食诱导的小鼠代谢紊乱的机制。方法:检测正常组、高果糖饮食组、青蒿素组及阳性药组小鼠血清葡萄糖、三酰甘油、胆固醇含量;采用超高效液相色谱-四极杆-飞行时间串联质谱法(UHPLC-Q-TOF MS)对各组小鼠血清进行代谢轮廓分析,进一步根据单变量统计分析筛选差异代谢物,对差异代谢物进行京都基因与基因组百科全书(KEGG)通路富集分析。结果:青蒿素显著降低了高果糖饮食诱导的小鼠血清三酰甘油上升。各组代谢轮廓出现改变。筛选出正离子模式下差异代谢物42个,负离子模式下差异代谢物45个。亚油酸代谢,逆行内源性大麻素信号转导,不饱和脂肪酸的生物合成等重要通路发生了显著改变。结论:青蒿素可以使高果糖饮食导致的代谢紊乱有所恢复,主要涉及脂质代谢。
Objective:To reveal the mechanism of artemisinin in treating the metabolic disorders induced by a high-fructose diet in mice based on the changes of serum metabolites.Methods:The levels of glucose,triglycerides,and cholesterol in the serum were measured for the mice in the control,high-fructose diet,artemisinin,and positive drug groups.Metabolic profiling was carried out by ultra-high performance liquid chromatography-quadrupole-time-of-flight tandem mass spectrometry(UHPLC-Q-TOF-MS/MS),and the differential metabolites were screened out by univariate statistical analysis.Furthermore,Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway enrichment was conducted for the differential metabolites.Results:Artemisinin significantly reduced the high-fructose diet-induced rise in the serum level of triglycerides in mice.The metabolic profiles were different among groups.Forty-two and 45 differential metabolites were screened out in the positive and negative ion modes,respectively.Changes occurred in the pathways such as linoleic acid metabolism,retrograde endocannabinoid signaling,and biosynthesis of unsaturated fatty acids.Conclusion:Artemisinin can restore the metabolic disorders caused by a high fructose diet,which mainly involves the lipid metabolism.
作者
李梦婷
董李晋川
陈颖
张红
杨紫玉
杨庆
刘丽
闫思超
蔡维艳
李琦
翁小刚
王娅杰
朱晓新
LI Mengting;DONG Lijinchuan;CHEN Ying;ZHANG Hong;YANG Ziyu;YANG Qing;LIU Li;YAN Sichao;CAI Weiyan;LI Qi;WENG Xiaogang;WANG Yajie;ZHU Xiaoxin(Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China)
出处
《世界中医药》
CAS
2023年第14期1952-1959,共8页
World Chinese Medicine
基金
国家自然科学基金项目(82074103)
国家自然科学基金项目(81803594)
国家“重大新药创制”科技重大专项(2017ZX09101002-002-008)
首都医科大学附属北京世纪坛医院基金项目(2021-C07)。